RAPP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

8 Analyst Rating

Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 53.00 USD with a low forecast of 34.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

34.00

Averages

53.00

High

80.00

Current: 0.000

Low

34.00

Averages

53.00

High

80.00

BTIG

NULL -> Buy

initiated

$47

2025-11-18

Reason

BTIG

Price Target

$47

2025-11-18

initiated

NULL -> Buy

Reason

BTIG initiated coverage of Rapport Therapeutics with a Buy rating and $47 price target. Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions, the analyst tells investors in a research note. BTIG has a high degree of confidence that the Phase 3 registrational focal epilepsy trials for RAP-219 will be successful and that the drug will receive approval.

Citizens JMP

Outperform

maintain

$77 -> $80

2025-11-07

Reason

Citizens JMP

Price Target

$77 -> $80

2025-11-07

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Rapport Therapeutics to $80 from $77 and keeps an Outperform rating on the shares. Rapport reported Q3 results and said it continues to advance RAP-219 development, the analyst tells investors in a research note. The firm continues to believe that the results from the Phase 2a proof-of-concept study evaluating RAP-219 in focal epilepsy can be rapidly and broadly adopted in clinical practice.

Truist

Joon Lee

Buy

initiated

$44

2025-09-16

Reason

Truist

Joon Lee

Price Target

$44

2025-09-16

initiated

Buy

Reason

Truist analyst Joon Lee initiated coverage of Rapport Therapeutics with a Buy rating and $44 price target. Rapport is focused on the central nervous system with a lead program in focal onset epilepsy, a therapeutic area worth $10B annually and growing, the analyst tells investors in a research note. The firm believes RAP-219's magnitude and speed of seizure reduction is \"impressive\" and models over$1B in peak sales in 2038 for focal onset epilepsy alone.

Goldman Sachs

Salveen Richter

maintain

$51

2025-09-12

Reason

Goldman Sachs

Salveen Richter

Price Target

$51

2025-09-12

maintain

Reason

Goldman Sachs analyst Salveen Richter assigned Rapport Therapeutics with a Buy rating and $51 price target from its Early-Stage Biotech designation. RAP-219's Phase 2 epilepsy data showed a 71% reduction in long episodes, the primary endpoint, with 24% achieving seizure freedom for the eight-week treatment period, the analyst tells investors in a research note. Goldman now views RAP-219 as well-positioned into the Phase 3 study given the Phase 2 \"de-risking.\"

H.C. Wainwright

Buy

upgrade

$31 -> $34

2025-09-08

Reason

H.C. Wainwright

Price Target

$31 -> $34

2025-09-08

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Rapport Therapeutics to $34 from $31 and keeps a Buy rating on the shares. The firm says RAP-219 surpassed its "most bullish expectations" with 71% reduction in long episodes and 78% reduction in clinical seizures. The data show "unimpeachable evidence" of the drug's effect and provide "strong evidence that it has the potential to become a mainstay" in the treatment of focal onset seizures, the analyst tells investors in a research note. H.C. Wainwright increased its probability of sucess for oral RAP-219 to 66% and peak revenue estimate to $766M from $613M.

Stifel

Buy

maintain

$35 -> $56

2025-09-08

Reason

Stifel

Price Target

$35 -> $56

2025-09-08

maintain

Buy

Reason

Stifel raised the firm's price target on Rapport Therapeutics to $56 from $35 and keeps a Buy rating on the shares after the company reported topline RAP-219 Phase 2a data in focal onset seizures that the firm says "clearly exceeded expectations." The effect-size is "so large that we are increasingly confident" in the probability-of-success for the Phase 3 trial, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Rapport Therapeutics Inc (RAPP.O) is -8.70, compared to its 5-year average forward P/E of -6.25. For a more detailed relative valuation and DCF analysis to assess Rapport Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.25

Current PE

-8.70

Overvalued PE

-3.90

Undervalued PE

-8.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.62

Current EV/EBITDA

-5.08

Overvalued EV/EBITDA

-1.08

Undervalued EV/EBITDA

-6.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RAPP News & Events

Events Timeline

No data

News

9.0

01-08NASDAQ.COM

Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials

6.5

2025-12-22Fool

Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $94.82 Million

6.0

2025-12-22NASDAQ.COM

Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $61.38 Million

People Also Watch

Frequently Asked Questions

What is Rapport Therapeutics Inc (RAPP) stock price today?

The current price of RAPP is 28.31 USD — it has decreased -6.01 % in the last trading day.

What is Rapport Therapeutics Inc (RAPP)'s business?

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

What is the price predicton of RAPP Stock?

What is Rapport Therapeutics Inc (RAPP)'s revenue for the last quarter?

Rapport Therapeutics Inc revenue for the last quarter amounts to -29.99M USD, increased 38.57 % YoY.

What is Rapport Therapeutics Inc (RAPP)'s earnings per share (EPS) for the last quarter?

Rapport Therapeutics Inc. EPS for the last quarter amounts to -17599000.00 USD, increased 6.31 % YoY.

What changes have occurred in the market's expectations for Rapport Therapeutics Inc (RAPP)'s fundamentals?

The market is revising No Change the revenue expectations for Rapport Therapeutics, Inc. (RAPP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 4.62%.

How many employees does Rapport Therapeutics Inc (RAPP). have?

Rapport Therapeutics Inc (RAPP) has 69 emplpoyees as of January 09 2026.

What is Rapport Therapeutics Inc (RAPP) market cap?

Today RAPP has the market capitalization of 1.35B USD.